WallStSmart

Berkshire Hathaway Inc (BRK-B)vsFold Holdings, Inc. Class A Common Stock (FLD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Berkshire Hathaway Inc generates 1168194% more annual revenue ($371.44B vs $31.79M). BRK-B leads profitability with a 18.0% profit margin vs -218.9%. BRK-B earns a higher WallStSmart Score of 54/100 (C-).

BRK-B

Buy

54

out of 100

Grade: C-

Growth: 3.3Profit: 7.5Value: 5.0Quality: 8.0
Piotroski: 3/9Altman Z: 2.60

FLD

Buy

53

out of 100

Grade: C-

Growth: 8.0Profit: 4.0Value: 5.0Quality: 4.3
Piotroski: 5/9Altman Z: -4.00

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BRK-B6 strengths · Avg: 9.2/10
Market CapQuality
$1.03T10/10

Mega-cap, among the largest globally

Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Operating MarginProfitability
33.0%10/10

Strong operational efficiency at 33.0%

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

P/E RatioValuation
15.3x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$4.99B8/10

Generating 5.0B in free cash flow

FLD4 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Return on EquityProfitability
278.6%10/10

Every $100 of equity generates 279 in profit

Revenue GrowthGrowth
41.2%10/10

Revenue surging 41.2% year-over-year

EPS GrowthGrowth
1622.0%10/10

Earnings expanding 1622.0% YoY

Areas to Watch

BRK-B4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
10.062/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-2.5%2/10

Earnings declined 2.5%

FLD4 concerns · Avg: 2.0/10
Market CapQuality
$77.24M3/10

Smaller company, higher risk/reward

Free Cash FlowQuality
$-5.03M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
-4.002/10

Distress zone — elevated risk

Profit MarginProfitability
-218.9%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : BRK-B

The strongest argument for BRK-B centers on Market Cap, Price/Book, Operating Margin. Profitability is solid with margins at 18.0% and operating margin at 33.0%.

Bull Case : FLD

The strongest argument for FLD centers on Price/Book, Return on Equity, Revenue Growth. Revenue growth of 41.2% demonstrates continued momentum.

Bear Case : BRK-B

The primary concerns for BRK-B are Piotroski F-Score, PEG Ratio, Revenue Growth.

Bear Case : FLD

The primary concerns for FLD are Market Cap, Free Cash Flow, Altman Z-Score.

Key Dynamics to Monitor

BRK-B profiles as a declining stock while FLD is a hypergrowth play — different risk/reward profiles.

BRK-B carries more volatility with a beta of 0.70 — expect wider price swings.

FLD is growing revenue faster at 41.2% — sustainability is the question.

BRK-B generates stronger free cash flow (5.0B), providing more financial flexibility.

Bottom Line

BRK-B scores higher overall (54/100 vs 53/100), backed by strong 18.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Berkshire Hathaway Inc

FINANCIAL SERVICES · INSURANCE - DIVERSIFIED · USA

Berkshire Hathaway Inc. is an American multinational conglomerate holding company headquartered in Omaha, Nebraska, United States. The company wholly owns GEICO, Duracell, Dairy Queen, BNSF, Lubrizol, Fruit of the Loom, Helzberg Diamonds, Long & Foster, FlightSafety International, Pampered Chef, Forest River, and NetJets, and also owns 38.6% of Pilot Flying J; and significant minority holdings in public companies Kraft Heinz Company (26.7%), American Express (18.8%), The Coca-Cola Company (9.32%), Bank of America (11.9%), and Apple (6.3%).

Visit Website →

Fold Holdings, Inc. Class A Common Stock

FINANCIAL SERVICES · CAPITAL MARKETS · USA

Fold Holdings, Inc. (FLD) is a dynamic biotechnology firm focused on developing revolutionary therapies for severe genetic and rare diseases through cutting-edge research. The company boasts a promising product pipeline underpinned by proprietary technologies and strategic partnerships that enhance its competitive positioning in the market. Committed to scientific excellence and patient-centered solutions, Fold is poised for sustainable growth and value creation, making it a compelling investment opportunity in the evolving healthcare landscape.

Visit Website →

Want to dig deeper into these stocks?